Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can blood tests and scans track lymphoma in real time? new study aims to find out.

NCT ID NCT07514715

Knowledge-focused Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be delivered within strict time limits. The goal is to see if this real-time monitoring approach is feasible, not to test a new treatment. About 129 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood test for ctDNA analysis
What this could lead to
If successful, this could enable doctors to track cancer more accurately during treatment, potentially leading to better-tailored therapies.
What could go wrong
This is an early feasibility study, not testing a new treatment. It may show that real-time monitoring is not practical or does not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 129 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with aggressive B cell lymphoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria Participants must meet all of the following criteria to be included in the study: 1. Participant who understands and voluntarily signs an informed consent form prior to any study-specific assessment or procedure. 2. Age 18 or older at the time of signing the Informed Consent Form (ICF) 3. Histologically confirmed diagnosis, according to the WHO 2022 classification, of any of the following lymphomas: Aggressive B-cell lymphoma, including: * Diffuse large B-cell lymphoma, unspecified (DLBCL not specified) * High-grade B-cell lymphoma (LBHG), including: 1. With rearrangements of the MYC and BCL2 and/or BCL6 genes (double/triple hit) 2. Unspecified (i.e., no double/triple rearrangement) * Primary B-cell lymphoma of the mediastinum (PMBL) * Transformed indolent B-cell lymphoma, including: 1. Transformed follicular lymphoma (LFt) 2. Transformed marginal zone lymphoma (t-MZL) 3. Transformed, unspecified nodal or splenic B-cell lymphomas (NOS) 4. Presence of a measurable disease on pre-therapeutic PET imaging, defined as at least one two-dimensional measurable nodal lesion, defined as \> 1.5 cm in its largest dimension (and FDG-greedy lesion), or at least one two-dimensional measurable extranodal lesion, defined as \> 1.0 cm in its largest dimension (and FDG-hungry lesion). 5. Requiring standard first-line systemic treatment with curative intent 6. Person covered by a social security scheme 7. Person able to understand and speak French. Exclusion criteria Participants who meet any of the criteria below will not be eligible for inclusion / should be excluded from the study: 1. Systemic anticancer treatment of current lymphoma prior to inclusion in the study. All participants must be previously untreated for current lymphoma. Note: Short-term corticosteroid therapy (e.g., for symptom control or as part of diagnostic workup) is allowed prior to inclusion and is not an exclusion criterion. 2. Lymphomas associated with an immuno-privileged site (e.g., primary central nervous system lymphoma, primary testicular lymphoma, primary vitreoretinal lymphoma). 3. Absence of mandatory blood sampling for the analysis of circulating tumor DNA (ctDNA) during screening (pre-therapeutic sampling). 4. Absence of 18F-FDG PET examination performed within 2 months ≤ the date of signing the consent (mandatory pre-therapeutic PET imaging). 5. Pregnant, intending to be pregnant, or breastfeeding woman of childbearing potential 6. Any significant medical condition, laboratory abnormality, or psychiatric illness that may interfere with participation in this clinical study (in the opinion of the investigator) 7. Person deprived of liberty by judicial or administrative decision 8. Person hospitalized without their consent 9. Adult under legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aggressive B-cell lymphomas are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement marginal zone lymphoma Neoplasm, Residual primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aggressive B-cell lymphomas

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CENTRE HENRI BECQUEREL - Service Hématologie

    Rouen, 76038, France

  • CENTRE LEON BERARD - Service Hématologie

    Lyon, 69373, France

  • CH D'AVIGNON - HOPITAL HENRI DUFFAUT - Service d'Onco-Hématologie

    Avignon, 84000, France

  • CH DE VERSAILLES - HOPITAL ANDRE MIGNOT - Service Hématologie Adolescents et Jeunes Adultes

    Le Chesnay, 78157, France

  • CHD DE VENDEE - Service Hématologie

    La Roche-sur-Yon, 85925, France

  • CHRU NANCY - HÔPITAL BRABOIS - Service Hématologie

    Vandœuvre-lès-Nancy, 54511, France

  • CHU D'AMIENS - HOPITAL SUD - Service Hématologie Clinique et Thérapie Cellulaire

    Amiens, 80054, France

  • CHU D'ANGERS - Service des Maladies du Sang

    Angers, 49033, France

  • CHU DE BORDEAUX - HOPITAL HAUT-LEVEQUE - CENTRE FRANCOIS MAGENDIE - Service d'Hématologie et Thérapie Cellulaire

    Pessac, 33604, France

  • CHU DE GRENOBLE - Service Hématologie

    La Tronche, 38700, France

  • CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang

    Lille, 59037, France

  • CHU DE MONTPELLIER - Département d'Hématologie Clinique

    Montpellier, 34295, France

  • CHU DE NANTES - Service Hématologie

    Nantes, 44093, France

  • CHU DE POITIERS - HOPITAL DE LA MILETRIE - Service d'Oncologie Hématologique et Thérapie Cellulaire

    Poitiers, 86021, France

  • CHU DE REIMS - HOPITAL ROBERT DEBRE - Service Hématologie

    Reims, 51092, France

  • CHU DIJON BOURGOGNE - Service Hématologie Clinique

    Dijon, 21000, France

  • CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique

    Clermont-Ferrand, 63003, France

  • CHU JEAN MINJOZ - Service Hématologie

    Besançon, 25030, France

  • CHU LYON-SUD - Hématologie Clinique

    Pierre-Bénite, 69495, France

  • CHU ORLEANS - Service Oncologie Médicale

    Orléans, 45067, France

  • CHU PONTCHAILLOU - Hématologie Clinique

    Rennes, 35033, France

  • GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique

    Villejuif, 94085, France

  • HOPITAL COCHIN - Hématologie clinique

    Paris, 75014, France

  • HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique

    Paris, 75651, France

  • HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes

    Créteil, 94010, France

  • HOPITAL NECKER - Service Hématologie Adultes

    Paris, 75743, France

  • HOPITAL SAINT VINCENT-DE-PAUL - Service Hématologie Clinique

    Lille, 59020, France

  • HOPITAL SAINT-LOUIS - Service Hématologie Adolescents et Jeunes Adultes

    Paris, 75475, France

  • INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie

    Saint-Cloud, 92210, France

  • IUCT ONCOPOLE - Service Hématologie

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.